Arsenic toxicology: translating between experimental models and human pathology
- PMID: 21684831
- PMCID: PMC3230447
- DOI: 10.1289/ehp.1103441
Arsenic toxicology: translating between experimental models and human pathology
Abstract
Background: Chronic arsenic exposure is a worldwide health problem. How arsenic exposure promotes a variety of diseases is poorly understood, and specific relationships between experimental and human exposures are not established. We propose phenotypic anchoring as a means to unify experimental observations and disease outcomes.
Objectives: We examined the use of phenotypic anchors to translate experimental data to human pathology and investigated research needs for which phenotypic anchors need to be developed.
Methods: During a workshop, we discussed experimental systems investigating arsenic dose/exposure and phenotypic expression relationships and human disease responses to chronic arsenic exposure and identified knowledge gaps. In a literature review, we identified areas where data exist to support phenotypic anchoring of experimental results to pathologies from specific human exposures.
Discussion: Disease outcome is likely dependent on cell-type-specific responses and interaction with individual genetics, other toxicants, and infectious agents. Potential phenotypic anchors include target tissue dosimetry, gene expression and epigenetic profiles, and tissue biomarkers.
Conclusions: Translation to human populations requires more extensive profiling of human samples along with high-quality dosimetry. Anchoring results by gene expression and epigenetic profiling has great promise for data unification. Genetic predisposition of individuals affects disease outcome. Interactions with infectious agents, particularly viruses, may explain some species-specific differences between human pathologies and experimental animal pathologies. Invertebrate systems amenable to genetic manipulation offer potential for elaborating impacts of specific biochemical pathways. Anchoring experimental results to specific human exposures will accelerate understanding of mechanisms of arsenic-induced human disease.
Conflict of interest statement
The authors declare they have no actual or potential competing financial interests.
References
-
- Agency for Toxic Substances and Disease Registry. Atlanta, GA: U.S. Department of Health and Human Services; 2007. Toxicological Profile for Arsenic. - PubMed
-
- Au WY, Kwong YL. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol. 2005;53:890–892. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21ES015812-02S2/ES/NIEHS NIH HHS/United States
- P30 ES006694/ES/NIEHS NIH HHS/United States
- P42ES004940/ES/NIEHS NIH HHS/United States
- P30 ES006096/ES/NIEHS NIH HHS/United States
- P42 ES004940/ES/NIEHS NIH HHS/United States
- P30ES006096/ES/NIEHS NIH HHS/United States
- R21ES017235/ES/NIEHS NIH HHS/United States
- R01 ES013781/ES/NIEHS NIH HHS/United States
- R21ES01581/ES/NIEHS NIH HHS/United States
- R21 ES017235/ES/NIEHS NIH HHS/United States
- P30 ES014443/ES/NIEHS NIH HHS/United States
- R01ES013781-02S1/ES/NIEHS NIH HHS/United States
- P30ES006694/ES/NIEHS NIH HHS/United States
- R01 ES010807/ES/NIEHS NIH HHS/United States
- P30ES014443/ES/NIEHS NIH HHS/United States
- R01ES010807/ES/NIEHS NIH HHS/United States
- R21 ES015812/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
